desonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
steroids for topical use, acetal derivatives 3135 638-94-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desonide
  • budesonide acetonide
  • prednacinolone
A nonfluorinated corticosteroid anti-inflammatory agent used topically for DERMATOSES.
  • Molecular weight: 416.51
  • Formula: C24H32O6
  • CLOGP: 2.37
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 93.06
  • ALOGS: -3.85
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 4, 1972 FDA PERRIGO NEW YORK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 681.95 21.87 158 2664 14230 50588072
Drug ineffective 143.82 21.87 199 2623 819134 49783168
Psoriasis 137.70 21.87 70 2752 68930 50533372
Dermatitis atopic 45.72 21.87 14 2808 3572 50598730
Cutaneous T-cell lymphoma 44.64 21.87 11 2811 1253 50601049
Eczema 31.10 21.87 18 2804 22684 50579618
Iridoschisis 29.17 21.87 4 2818 14 50602288
Chronic sinusitis 24.10 21.87 10 2812 6135 50596167

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 92.99 22.99 43 1723 32184 29540577
Hepatic lesion 26.02 22.99 9 1757 3141 29569620

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 150.14 20.04 74 3349 71629 64423680
Dermatitis atopic 41.13 20.04 13 3410 3863 64491446
Cutaneous T-cell lymphoma 38.41 20.04 11 3412 2341 64492968
Application site pain 32.01 20.04 11 3412 4237 64491072
Product dose omission issue 30.24 20.04 44 3379 194703 64300606
Iridoschisis 29.36 20.04 4 3419 14 64495295
Macular degeneration 28.83 20.04 11 3412 5699 64489610
Pruritus 27.75 20.04 55 3368 312345 64182964
Dry skin 24.72 20.04 21 3402 51140 64444169
Dry eye 23.02 20.04 16 3407 29003 64466306
Eczema 22.68 20.04 16 3407 29704 64465605
Eye swelling 21.81 20.04 14 3409 22267 64473042
Hepatic lesion 21.66 20.04 9 3414 5815 64489494
Chronic sinusitis 20.99 20.04 9 3414 6283 64489026

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D07AB08 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, moderately potent (group II)
ATC D07BB02 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
Corticosteroids, moderately potent, combinations with antiseptics
ATC S01BA11 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Corticosteroids, plain
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:35472 anti-inflammatory drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Otitis externa indication 3135009
Atopic dermatitis indication 24079001 DOID:3310
Crohn's disease indication 34000006
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Allergic rhinitis indication 61582004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Asthma indication 195967001 DOID:2841
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Asthma management indication 406162001
Crohn's disease in remission indication 426549001
Allergic Rhinitis Prevention indication
Chronic Non-Allergic Rhinitis indication
Severe chronic obstructive pulmonary disease off-label use 313299006
Otitis Externa Eczema off-label use
Otitis Externa Seborrhea off-label use
Infection by Strongyloides contraindication 1214006 DOID:10955
Mycosis contraindication 3218000 DOID:1564
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Inactive tuberculosis contraindication 11999007
Epistaxis contraindication 12441001
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Measles contraindication 14189004 DOID:8622
Disease caused by parasite contraindication 17322007
Cirrhosis of liver contraindication 19943007 DOID:5082
Arginase deficiency contraindication 23501004 DOID:9278
Glaucoma contraindication 23986001 DOID:1686
Acute tuberculosis contraindication 25629007
Viral disease contraindication 34014006 DOID:934
Immunosuppression contraindication 38013005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Hypercortisolism contraindication 47270006
Chronic heart failure contraindication 48447003
Cerebral malaria contraindication 53622003 DOID:14069
Tuberculosis contraindication 56717001
Perforation of tympanic membrane contraindication 60442001
Congenital hyperammonemia, type I contraindication 62522004
Osteoporosis contraindication 64859006 DOID:11476
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Perforation of nasal septum contraindication 80142000
Hyperglycemia contraindication 80394007 DOID:4195
Open-angle glaucoma contraindication 84494001 DOID:1067
Bacterial infectious disease contraindication 87628006
Muscle atrophy contraindication 88092000 DOID:767
Herpes simplex contraindication 88594005 DOID:8566
Operation on nose contraindication 88733004
Bilateral cataracts contraindication 95722004
Seizure disorder contraindication 128613002
Disorder of muscle contraindication 129565002 DOID:423
Pulmonary tuberculosis contraindication 154283005 DOID:2957
Ophthalmic herpes simplex contraindication 186542001
Anastomosis of intestine contraindication 235407009
Disease of liver contraindication 235856003 DOID:409
Telangiectasia disorder contraindication 247479008
Edema contraindication 267038008
Pathological fracture contraindication 268029009
Diverticulitis of gastrointestinal tract contraindication 271366000
Cerebral trauma contraindication 275382005
Varicella-zoster virus infection contraindication 309465005
Osteopenia contraindication 312894000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Avascular necrosis of bone contraindication 397758007 DOID:10159
Citrullinemia contraindication 398680004 DOID:9273
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006
Traumatic rupture of tendon contraindication 415749005
Exposure to varicella contraindication 444453009
Nasal Candidiasis contraindication
Untreated Fungal Infection contraindication
Uncontrolled Bacterial Infections contraindication
Nasal Septal Ulcers contraindication
Ornithine Carbamyltransferase Deficiency contraindication
Nasal Trauma contraindication
Arginosuccinate Lyase Deficiency contraindication
Oropharyngeal Candidiasis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.78 acidic
pKa2 12.78 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.05% VERDESO ALMIRALL N021978 Sept. 19, 2006 RX AEROSOL, FOAM TOPICAL 8962000 Aug. 31, 2025 TREATMENT OF ATOPIC DERMATITIS
0.05% VERDESO ALMIRALL N021978 Sept. 19, 2006 RX AEROSOL, FOAM TOPICAL 9492384 Aug. 31, 2025 TREATMENT OF ATOPIC DERMATITIS
0.05% VERDESO ALMIRALL N021978 Sept. 19, 2006 RX AEROSOL, FOAM TOPICAL 8460641 Aug. 13, 2027 TREATMENT OF ATOPIC DERMATITIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4018267 VUID
N0000146597 NUI
D03696 KEGG_DRUG
4018267 VANDF
C0011705 UMLSCUI
CHEBI:204734 CHEBI
CHEMBL1201109 ChEMBL_ID
D003898 MESH_DESCRIPTOR_UI
DB01260 DRUGBANK_ID
5311066 PUBCHEM_CID
7066 IUPHAR_LIGAND_ID
2889 INN_ID
J280872D1O UNII
3254 RXNORM
1093 MMSL
4550 MMSL
002199 NDDF
412363005 SNOMEDCT_US
52215008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0115-1517 LOTION 0.50 mg TOPICAL ANDA 17 sections
desonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0309 OINTMENT 0.50 mg TOPICAL ANDA 17 sections
desonide HUMAN PRESCRIPTION DRUG LABEL 1 0168-0310 LOTION 0.50 mg TOPICAL ANDA 19 sections
DesOwen HUMAN PRESCRIPTION DRUG LABEL 1 0299-5765 LOTION 0.50 mg TOPICAL ANDA 18 sections
DesOwen HUMAN PRESCRIPTION DRUG LABEL 1 0299-5770 CREAM 0.50 mg TOPICAL NDA 18 sections
LoKara HUMAN PRESCRIPTION DRUG LABEL 1 0462-0392 LOTION 0.50 mg TOPICAL ANDA 18 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0472-0803 LOTION 0.50 mg TOPICAL ANDA 19 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0472-0804 CREAM 0.50 mg TOPICAL NDA authorized generic 19 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0713-0661 CREAM 0.50 mg TOPICAL ANDA 18 sections
DESONATE HUMAN PRESCRIPTION DRUG LABEL 1 10922-828 GEL 0.50 mg TOPICAL NDA 24 sections
Verdeso HUMAN PRESCRIPTION DRUG LABEL 1 16110-111 AEROSOL, FOAM 0.50 mg TOPICAL NDA 26 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 16714-729 CREAM 0.50 mg TOPICAL ANDA 21 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 16714-828 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
DESONIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-944 CREAM 0.50 mg TOPICAL ANDA 21 sections
Desonide Ointment, 0.05% HUMAN PRESCRIPTION DRUG LABEL 1 21922-004 OINTMENT 0.50 mg TOPICAL ANDA 18 sections
DESONIDE HUMAN PRESCRIPTION DRUG LABEL 1 24470-920 GEL 0.50 mg TOPICAL ANDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 42254-142 CREAM 0.50 mg TOPICAL NDA 20 sections
DESRX HUMAN PRESCRIPTION DRUG LABEL 1 44118-710 GEL 0.50 mg TOPICAL ANDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 45802-422 CREAM 0.50 mg TOPICAL NDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 45802-422 CREAM 0.50 mg TOPICAL NDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 45802-423 OINTMENT 0.50 mg TOPICAL NDA 20 sections
DESONATE HUMAN PRESCRIPTION DRUG LABEL 1 50222-504 GEL 0.50 mg TOPICAL NDA 24 sections
DESONATE HUMAN PRESCRIPTION DRUG LABEL 1 50419-828 GEL 0.50 mg TOPICAL NDA 24 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 51672-1280 CREAM 0.50 mg TOPICAL ANDA 21 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 51672-1281 OINTMENT 0.50 mg TOPICAL ANDA 21 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 51672-4079 LOTION 0.50 mg TOPICAL ANDA 21 sections
DESONIDE HUMAN PRESCRIPTION DRUG LABEL 1 52187-556 GEL 0.50 mg TOPICAL ANDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 52565-038 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 54868-3284 CREAM 0.50 mg TOPICAL NDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 54868-4453 OINTMENT 0.50 mg TOPICAL NDA 20 sections